Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.42 |
| ▸ | ITGAV | P06756 | 14/20 | 0.42 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5778299 | 0.91 | CNR2 (0.45) | CNR2CNR1 | |
| SCHEMBL5779626 | 0.91 | ITGB3 (0.43) | ITGB3ITGAVITGA2BEGLN2EGLN1 | |
| SCHEMBL5782259 | 0.89 | ITGB3 (0.41) | ITGB3ITGAVCNR2CNR1ITGA2B | |
| SCHEMBL5780955 | 0.85 | ITGB3 (0.57) | ITGB3ITGAVITGA2BEGLN2EGLN1 | |
| SCHEMBL1071518 | 0.84 | ITGB3 (0.40) | ITGB3ITGAVITGA2B | |
| SCHEMBL5778802 | 0.82 | CNR2 (0.45) | ITGB3ITGAVCNR2CNR1ITGA2B | |
| SCHEMBL5780692 | 0.82 | ITGAV (0.55) | ITGB3ITGAVCNR2CNR1ITGA2B | |
| SCHEMBL5779214 | 0.81 | CNR2 (0.41) | ITGB3ITGAVCNR2CNR1 | |
| SCHEMBL5778333 | 0.80 | CNR1 (0.38) | ITGB3ITGAVCNR2CNR1ITGA2B | |
| SCHEMBL5779660 | 0.80 | ITGB3 (0.42) | ITGB3ITGAVITGA2BEGLN2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0944619-B1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2006-10-11 | — | — | EP | claimed |
| EP-0944619-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 1999-09-29 | — | — | EP | claimed |
| WO-1998023608-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-06-04 | — | — | WO | claimed |
| EP-0944619-B1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2006-10-11 | — | — | EP | disclosed |
| US-6358976-B1 | FOR THERAPY AND PROPHYLAXIS OF CANCER METASTASIS, DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, THROMBOSIS, RESTENOSIS, OSTEOPOROSIS, OR MACULAR DEGENERATION | LANTHEUS MI REAL ESTATE, LLC | 2002-03-19 | — | — | US | disclosed |
| US-6130231-A | SUBSTITUTED 2,3-DIHYDROQUINOLIN-4-ONES | DUPONT PHARMACEUTICALS (US) | 2000-10-10 | — | — | US | disclosed |
| EP-0944619-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998023608-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |